Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Diarrhea 1Colitis 1

Interventions

Paclitaxel 2temsirolimus 1pembrolizumab 1dehydroftorafur 1Topotecan 1Platinum 1Oxaliplatin 1OSI 930 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1Loperamide 1Leucovorin 1Irinotecan 1Hyperthermic Intraperitoneal Chemotherapy 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fluorodeoxyglucose F18 1Fecal Microbiota Transplantation 1FAPI-46 1Doxorubicin 1Cisplatin 1Carboplatin 1Bortezomib 1Biopsy 14-hydroxy-N-desmethyltamoxifen 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uterine Neoplasms × Loperamide × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡